MedTrace Logo

Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency

NCT06620731 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-11-12

No results posted yet for this study

Summary

To evaluate and compare the safety and efficacy of FCN-437c in subjects with mild and moderate liver impairment and healthy subjects, and to provide a basis for clinical medication in patients with liver impairment.

Conditions

  • Hepatic Insufficiency

Interventions

DRUG

FCN-437c capsule

Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.

Sponsors & Collaborators

  • Ahon Pharmaceutical Co., Ltd.

    lead OTHER

Principal Investigators

  • Yanhua Ding, PI · The First Hospital of Jilin University

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-04
Primary Completion
2023-09-27
Completion
2023-09-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06620731 on ClinicalTrials.gov